Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 12, 2019 4:05 PM ESTNew Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last Visit Implemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020 Received CE Mark Approval for Renevia®; Working to Identify European Commercial Partner Conducted Sales of 6.25 Million Shares of OncoCyte Corporation for $10.7 Million in Net Proceeds Strengthened Extensive IP Portfolio with the Issuance of 3 New U.S. Patents Awarded Additional NIH Grant for Innovative Vision Restoration Program
CARLSBAD,... More
